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Abstract
Background: Phenytoin (PHT) has been reported to induce gingival (gum) overgrowth (GO) in approximately 50%
of patients taking this medication. While most studies have focused on the effects of PHT on the fibroblast in the
pathophysiology underlying GO, few studies have investigated the potential regulatory role of macrophages in
extracellular matrix (ECM) turnover and secretion of proinflammatory mediators. The aim of this study was to
evaluate the effects of PHT and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin (HPPH) on LPS-elicited
MMP, TIMP, TNF-a and IL-6 levels in macrophages.
Methods: Human primary monocyte-derived macrophages (n = 6 independent donors) were pretreated with 15-
50 μg/mL PHT-Na+ or 15-50 μg/mL HPPH for 1 hour. Cells were then challenged with 100 ng/ml purified LPS from
the periodontal pathogen, Aggregatibacter actinomycetemcomitans. Supernatants were collected after 24 hours and
levels of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, TIMP-1, TIMP-2, TIMP-3, TIMP-4, TNF-a and IL-6 determined by
multiplex analysis or enzyme-linked immunoadsorbent assay.
Results: A dose-dependent inhibition of MMP-1, MMP-3, MMP-9, TIMP-1 but not MMP-2 was noted in culture
supernatants pretreated with PHT or HPPH prior to LPS challenge. MMP-12, TIMP-2, TIMP-3 and TIMP-2 were not
detected in culture supernatants. High concentrations of PHT but not HPPH, blunted LPS-induced TNF-a
production although neither significantly affected IL-6 levels.
Conclusion: The ability of macrophages to mediate turnover of ECM via the production of metalloproteinases is
compromised not only by PHT, but its metabolite, HPPH in a dose-dependent fashion. Further, the preferential
dysregulation of macrophage-derived TNF-a but not IL-6 in response to bacterial challenge may provide an
inflammatory environment facilitating collagen accumulation without the counteracting production of MMPs.
Background
Drug-induced gingival (gum) overgrowth (DIGO) is
widely recognized as a common unwanted sequelae
associated with a variety of medications. Among these,
the antiepileptic agent, PHT (Dilantin®), has been
reported to induce gingival overgrowth (GO) in approxi-
mately 50% of patients taking this medication [1,2]. PHT
is a hydantoin-derivative anticonvulsant that exerts its
anticonvulsant properties by stabilizing neuronal cell
membranes to the action of sodium, potassium, and cal-
cium. The drug also affects the transport of calcium
across cell membranes and decreases the influx of cal-
cium ions across membranes by decreasing membrane
permeability and blocking intracellular uptake [3]. PHT
is primarily metabolized by liver cytochrome P450
enzymes, particularly CYP2C9 and CYP2C19 [4] to form
enantiomers of 5-(4-hydroxyphenyl-),5-phenylhydantoin
(HPPH) which in addition to PHT, have been implicated
in the pathogenesis of DIGO [5,6].* Correspondence: Salvador_Nares@dentistry.unc.edu1Department of Periodontology, School of Dentistry, University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
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While most studies have focused on the role of the
fibroblast [7-10], it is likely that other cells contribute to
the pathogenesis of DIGO. In particular, tissue macro-
phages, present in elevated numbers within gingival tis-
sues, possibly in response to accumulation of the plaque
biofilm [2,11], may play a role in pathogenesis. These
long-lived, multifaceted cells, strategically poised along
portals of entry, perform numerous functions of vital
importance to the host. In addition to their key role in
immunity [12], the macrophage is recognized as the
major mediator of normal connective tissue turnover
and maintenance, as well as for orchestrating repair dur-
ing wound healing [13-18]. It has a dualistic role to
receive, amplify, and transmit signals to fibroblasts,
endothelial cells, and vascular smooth muscle cells by
producing pro-inflammatory and catabolic cytokines.
However, during tissue turnover and wound healing it
secretes anabolic peptide growth factors [12]. Given this
duality of function, any perturbation can lead to patho-
logical processes. We have demonstrated that the clini-
cal presentation of PHT-induced gingival overgrowth is
associated with a specific macrophage phenotype char-
acterized by high expression levels of IL-1b and PDGF-
B [11,19] suggesting that this drug-induced macrophage
phenotype could contribute to the pathogenesis of
DIGO. These cellular attributes might explain the
dichotomy of the lesion where there is both periodontal
inflammation typically associated with connective tissue
catabolism paradoxically juxtaposed with gingival over-
growth,- a clear anabolic signal of wound repair and
regeneration.
As tissue homeostasis requires the proper balance of
metabolism and catabolism, it is possible that macro-
phage-derived cytokines, MMPs and TIMP levels are
altered in response to PHT and HPPH. Here we investi-
gated the effects of these agents on production of
MMPs, TIMPs, and pro-inflammatory cytokines in
human monocyte-derived macrophages and report that
indeed, PHT and HPPH significantly modulate macro-
phage MMP and cytokine protein levels in response to
purified LPS from the periodontal pathogen, Aggregati-
bacter actinomycetemcomitans.
Methods
Monocyte isolation and macrophage differentiation
Peripheral blood mononuclear cells were obtained from
commercially-available buffy coats (Oklahoma Blood
Institute, Oklahoma City, OK, USA) derived from
healthy donors by density gradient centrifugation using
Ficoll-paque (Amersham, Uppsala, Sweden). Six inde-
pendent cultures were obtained from 6 independent
donors. Monocytes were isolated using CD14 MicroBe-
ads (Miltenyi Biotec, Auburn, CA, USA) according to
manufacturer’s instructions and cultured as previously
described [12,20,21]. Briefly, isolated monocytes were
plated onto duplicate 12-well tissue culture-treated
plates (BD Biosciences, San Jose, CA, USA) at a density
of 5 × 105 cells/cm2 in serum-free DMEM with L-gluta-
mine (Cellgro, Manassas, VA, USA) containing 50 μg/
mL gentamicin (Sigma, St. Louis, MO, USA) at 37 C,
5% CO2 to promote monocyte attachment. After 2
hours, heat-inactivated fetal bovine serum (FBS, Invitro-
gen, Carlsbad, CA, USA) was added to a final concentra-
tion of 10%. Cells were >95% CD14+ as determined by
FACS analysis (data not shown) prior to culture.
Macrophage stimulation
After 5 days, the media and non-adhered cells were
removed and replaced with complete media (DMEM,
10% FBS, gentamicin) and incubated at 37 C, 5% CO2.
Media was replaced every 2 days. Experiments were
initiated upon confirmation of macrophage differentia-
tion after 7 days in culture [12,20,21]. Macrophages
were used between day 7 and 10 and pretreated with
either: 1) 15 μg/mL of PHT-Na+ (Sigma), (serum levels,
[22-24]), 2) 50 μg/mL PHT-Na+ (high dose), 3) 15 μg/
mL PHT metabolite (Sigma), (5-(4’-hydroxyphenyl),5-
phenylhydantoin, HPPH), or 4) 50 μg/mL HPPH for 1
hour. Untreated cells served as control cultures. Stock
solutions of PHT-Na+ (150 mg/mL) were made in ster-
ile deionized water while HPPH (150 mg/mL) solutions
were made in DMSO. Each stock solution was further
diluted prior to use. The total concentration of DMSO
in cultures was always less than 0.05%. DMSO concen-
trations less than 0.1% have been reported not to affect
cellular viability and function [25,26]. Nevertheless, we
confirmed these findings in preliminary studies exposing
macrophage cultures to 0.05% DMSO (data not shown).
To induce production of MMPs and proinflammatory
cytokines, macrophages were challenged with 100 ng/
mL purified LPS from the Gram-negative, periodontal
pathogen, Aggregatibacter actinomycetemcomitans
(A. actinomycetemcomitans (Aa), serotype b, strain Y4, a
kind gift from K. L. Kirkwood, University of South Car-
olina, USA) for 24 hours. Isolation and purification of
Aa LPS has been previously described [27]. Previous stu-
dies have demonstrated that LPS from this organism is
capable of inducing MMP and TIMP production [28-30]
and our preliminary studies determined that this con-
centration of LPS was capable of significantly inducing
TNF-a levels in human primary macrophages and THP-
1 cells induced for macrophage differentiation (data not
shown).
MMP, TIMP protein assays
After 24 hours, the media was collected, spun at 12,000 ×
g, transferred to fresh tubes and stored at -80 C until
further use. Quantification of supernatant MMP and
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TIMP levels were determined using the Luminex 100
System (Luminex Co., Austin, TX, USA) and the Fluoro-
kine MAP Multiplex Human MMP Panel and the Fluoro-
kine MAP Human TIMP Multiplex Kit, respectively
according to the manufacturer’s instructions (both from
R & D, Minneapolis, MN, USA). These kits measure
levels of pro-, mature, and TIMP complexed MMPs. Six
independent experiments were performed from cells
derived from 6 different donors. The assays were per-
formed in 96-well plates, as previously described [20].
For MMP determination, microsphere beads coated with
monoclonal antibodies against MMP-1, MMP-2, MMP-
3, MMP-9, MMP-12 were added to the wells. For TIMP
determination, microsphere beads coated with monoclo-
nal antibodies against TIMP-1, TIMP-2, TIMP-3, and
TIMP-4 were added to the wells of a separate plate. To
remain below the upper level of quantitation, samples
containing LPS were diluted 10-fold prior to analysis.
This dilution factor was based on our preliminary studies.
Samples and standards were pipetted into wells, incu-
bated for 2 hours with the beads then washed using a
vacuum manifold (Millipore Corporation, Billerica, MA
USA). Biotinylated secondary antibodies were added and
incubation for 1 h. The beads were then washed and
incubated for an additional 30 minutes with streptavidin
conjugated to the fluorescent protein, R-phycoerythrin
(streptavidin/R-phycoerythrin). The beads were washed
and analyzed (a minimum of 50 per analyte) using the
Luminex 100 system. The Luminex 100 measures the
amount of fluorescence associated with R-phycoerythrin,
reported as median fluorescence intensity of each spec-
tral-specific bead allowing it to distinguish the different
analytes in each well. The concentrations of the unknown
samples (antigens in macrophage supernatants) were esti-
mated from the standard curve using a third-order poly-
nomial equation and expressed as pg/mL after adjusting
for the dilution factor. Samples below the detection limit
of the assay were recorded as zero. The minimum detect-
able concentrations for the assays were as follows: MMP-
1: 4.4 pg/mL, MMP-2: 25.4 pg/mL, MMP-3: 1.3 pg/mL,
MMP-9: 7.4 pg/mL, TIMP-1: 1.54 pg/mL, TIMP-2: 14.7
pg/mL, TIMP-3: 86 pg/mL and TIMP-4: 1.29 pg/mL. All
values were standardized for total protein using the Brad-
ford assay (Pierce, Thermo Scientific, Rockford, IL, USA)
according to manufacturer’s instructions. Briefly, culture
supernatants were mixed with assay reagent and incu-
bated for 10 minutes at room temperature in 96 well
plates. Bovine serum albumin (BSA, Invitrogen) was used
as a standard. The absorbance at 595 nm was read using
a SpectraMax M2 microplate reader (Molecular Devices,
Sunnyvale, CA, USA). Values obtained from untreated
control cultures were arbitrarily used as a baseline mea-
sure. The ratio, (control)/(supernatant protein value) was
used to normalize each sample based on total protein.
Cytokine assays
After 24 hours, supernatants (n = 6 independent
donors) were collected and levels of TNF-a and IL-6
determined by ELISA (RayBiotech, Norcross, GA, USA)
according to manufacturer’s instructions. The absor-
bance at 450 nm was read using a SpectraMax M2
microplate reader (Molecular Devices) with the wave-
length correction set at 550 nm. The rated sensitivities
of the commercial ELISA kits was 15 pg/mL for TNF-a
and 6 pg/mL for IL-6. Values were standardized for
total protein using the Bradford assay as described
above.
Cell viability assays
Viability of macrophages was evaluated using the CellTi-
ter 96 AQueous One Solution Cell Proliferation Assay
[3-(4,5-diethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt, MTS] assay
according to the manufacturer’s protocol (Promega,
Madison, WI, USA). This colorimetric method can be
used to determine the number of viable cells in prolif-
eration or to evaluate cytotoxicity. Briefly, macrophages
were cultured in triplicate in 96-well plates and treated
with PHT, HPPH and LPS as described above. Unstimu-
lated cells served as control cultures. After 24 h, the
cells were incubated with MTS for 2 h at 37 C, 5% CO2.
The absorbance was read at 490 nm using a microplate
reader.
Statistical analysis
Data were analyzed using a hierarchical multiple regres-
sion approach relative to LPS, drug and dose. The first
tier sought to establish the validity of the positive con-
trol, LPS vs the negative control group. The second tier
of this analysis was aimed at determining whether PHT
or HPPH have an effect on MMP, TIMP, TNF-a and
IL-6 levels. Finally, the third tier sought to contrast dose
and compare one drug with another. Data were
expressed as mean ± SEM and compared using a two-
tailed Student’s t test for correlated samples (GraphPad
Prism, GraphPad Software, La Jolla, CA, USA). Results
were considered statistically significant at p < 0.05.
Results
PHT and HPPH inhibit LPS-induced supernatant levels of
MMP-1, MMP-3, MMP-9, and TIMP-1 in a dose dependent
manner
To evaluate the effects of PHT and its metabolite,
HPPH on macrophage MMP and TIMP levels, human
monocyte-derived macrophages were pretreated for 1
hour with either 15 μg/mL or 50 μg/mL of these agents
prior to challenge with LPS. Previous studies have deter-
mined that PHT plasma levels of 10-20 μg/mL are
necessary to effectively maintain effective seizure control
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[22-24]. Thus, the concentrations used in our study
represent therapeutic as well as elevated levels of PHT
permitting the evaluation of dose on MMP and TIMP
production. To rule out the possibility that differences
in supernatant levels of these readouts were due to
decreased cell viability, we performed a viability assay
on cells cultured in each condition. No significant differ-
ences were noted in the viability of cells exposed to LPS
and either dose of PHT, HPPH, PHT/LPS or HPPH/
LPS as determined by MTS assay. Further, we standar-
dized the results of each analyte to total protein concen-
tration for each condition using a Bradford assay. No
differences were noted for any analyte examined in con-
ditioned media from macrophage cultures treated with
PHT or HPPH alone compared to control cultures (p >
0.05). As expected, LPS markedly induced supernatant
MMP-1, MMP-3, MMP-9, TIMP-1 but not MMP-2
levels in our 6 independent cultures after a 24 hour
exposure (Fig. 1A-D). Compared to untreated control
cultures, LPS significantly increased secretion of MMP-1
despite the presence of either PHT or HPPH at any
dose. This was similarly observed for MMP-3 levels with
the exception of cultures pretreated with 15 μg/mL
HPPH which despite elevated levels, did not reach sta-
tistical significance (p > 0.05). In contrast, exposure of
macrophages to 50 μg/mL of either PHT or HPPH prior
to LPS stimulation prevented a significant increase in
MMP-9 and TIMP-1 (Fig. 1D and Fig. 2). Levels of
Figure 1 The effect of phenytoin, HPPH and LPS on levels of (A) matrix metalloproteinase-1, (B) matrix metalloproteinase-2, (C) matrix
metalloproteinase-3, and (D) matrix metalloproteinase-9 in conditioned medium from macrophage cultures. Primary human monocyte-
derived macrophages (n=6 independent cultures) were pretreated with phenytoin or HPPH (15 μg/mL and 50 μg/mL) for 1 hour prior to
challenge with 100 ng/mL A. actinomycetemcomitans LPS and the levels of matrix metalloproteinase-1, matrix metalloproteinase-2, matrix
metalloproteinase-3, and matrix metalloproteinase-9 measured after 24 hours in conditioned media by multiplex analysis. MMP-1, matrix
metalloproteinase-1; MMP-2, matrix metalloproteinase-2; MMP-3, matrix metalloproteinase-3; MMP-9, matrix metalloproteinase-9; CON, control;
PHT, phenytoin; HPPH, 5-(4-hydroxyphenyl-),5- phenylhydantoin; LPS, lipopolysaccharide. Compared to CON, # p<0.05, ## p<0.01, ### p<0.001,
compared to LPS, * p<0.05, ** p<0.01, *** p<0.001. Student t-test, n=6 independent donors.
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MMP-9 and TIMP-1 remained near control levels
despite the potent proinflammatory challenge thus
demonstrating the ability of these agents to alter macro-
phage function. Compared to LPS alone, pretreatment
with 50 μg/mL PHT significantly blunted LPS-induced
levels of MMP-1 (p < 0.05). In cultures pretreated with
50 μg/mL HPPH, MMP-3 levels were not significantly
different compared to LPS-only treated cultures (p >
0.05) although the trend for reduced supernatant levels
of MMP3 was evident. However, exposure of macro-
phages to either 15 μg/mL or 50 μg/mL PHT prior to
LPS stimulation significantly blunted supernatant MMP-
3 levels (p < 0.01 and p < 0.001, respectively, Fig. 1C)
compared to LPS-only treated cultures. Interestingly, a
trend for higher levels of MMP-1 were noted in cultures
treated with HPPH while MMP-3 levels were slightly
elevated in cultures treated with either PHT and HPPH
although neither reached statistical significance (p >
0.05) (Fig. 1, A, C).
Elevated levels (50 μg/mL) of PHT or HPPH signifi-
cantly reduced MMP-9 and TIMP-1 levels compared to
LPS-only treated cells (Fig. 1D and Fig. 2). The levels of
these analytes remained near control values despite LPS
challenge. Interestingly, HPPH but not PHT was
associated with reduced levels of MMP-2 compared to
LPS only, but this relationship was not statistically sig-
nificant. MMP-12 and TIMPs-2-4 remained below levels
of detection in all groups and cultures.
Supernatant levels of TNF-a but not IL-6, is decreased in
response to PHT
At 24 hours, supernatant levels of TNF-a and IL-6
were significantly increased by LPS compared to
untreated controls (p < 0.001). Similar to MMP and
TIMP levels, no significant differences in TNF-a and
IL-6 levels were observed in supernatants exposed to
either 15 or 50 μg/mL PHT and HPPH alone com-
pared to untreated cultures although a trend for
decreased levels of TNF-a was evident (Fig 3A). How-
ever, macrophage cultures pretreated with 50 μg/mL
PHT prior to challenge with LPS showed a significant
(p < 0.05) decrease in TNF-a levels compared to LPS
only treated cultures. No difference was noted for 15
μg/mL of PHT or HPPH at either concentration (Fig.
3A). Regardless of dosage, pretreatment with PHT or
HPPH prior to LPS challenge had no significant effect
(p > 0.05) on IL-6 secretion when compared to LPS
only treated cultures.
Figure 2 The effect of phenytoin, HPPH and LPS on levels of tissue inhibitor of matrix metalloproteinase-1 in conditioned medium
from macrophage cultures. Primary human monocyte-derived macrophages (n = 6 independent cultures) were pretreated with phenytoin or
HPPH (15 μg/mL and 50 μg/mL) for 1 hour prior to challenge with 100 ng/mL A. actinomycetemcomitans LPS and the levels of tissue inhibitor of
matrix metalloproteinase-1 measured after 24 hours in conditioned media by multiplex analysis. TIMP-1, tissue inhibitor of matrix
metalloproteinase-1; CON, control; PHT, phenytoin; HPPH, 5-(4-hydroxyphenyl-),5-phenylhydantoin; LPS, lipopolysaccharide. Compared to CON, #
p < 0.05, ## p < 0.01, ### p < 0.001, compared to LPS, * p < 0.05, ** p < 0.01, *** p < 0.001. Student t-test, n = 6 independent donors.
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Discussion
Macrophages are involved in a remarkably diverse array
of homeostatic processes of vital importance to the host.
In addition to their critical role in immunity [12],
macrophages are also widely recognized as ubiquitous
mediators of cellular turnover and maintenance of extra-
cellular matrix homeostasis [13-18]. However, beyond
their essentiality in immunity and tissue homeostasis,
the macrophage has also been implicated in the evolu-
tion of periodontal pathological processes including per-
iodontal disease and DIGO [11,19,20,31,32]. This
investigation posited that macrophage-derived expres-
sion of proinflammatory cytokines, MMPs and/or TIMP
expression is blunted upon exposure to PHT and/or
HPPH hindering the ability of these cells to contribute
to the fibroblast-mediated degradation of exuberant
ECM proteins seen in DIGO. Since plaque-induced gin-
gival inflammation exacerbates the manifestations of
PHT-induced GO [33], we exposed macrophage cultures
to purified LPS from the periodontal pathogen, A. acti-
nomycetemcomitans (Aa) and examined protein levels of
MMPs, TIMPs and proinflammatory cytokines in condi-
tioned media. Aa can be isolated from plaque samples
of patients with GO [34] while Aa LPS, a TLR4 agonist,
strongly induces MMP and pro-inflammatory cytokine
expression [28-30,35].
We exposed macrophage cultures to 2 different con-
centrations of PHT and HPPH. And while PHT plasma
levels of 10-20 μg/mL are necessary to effectively main-
tain effective seizure control [22-24], disturbances in
plasma as well as gingival concentrations of PHT are
likely associated with DIGO. Indeed, Güncü et al [36]
compared PHT levels in plasma and gingival crevicular
fluid (GCF), a serum exudate, from subjects who
demonstrated gingival overgrowth (responders) vs. those
who did not (non-responders). Although PHT was
detected in all of the GCF and plasma samples, the
mean concentration of PHT was significantly greater in
GCF compared to plasma (294.99 ± 430.15 μg/mL vs.
16.09 ± 4.21 μg/mL, respectively). Further, the concen-
tration of plasma PHT was significantly higher in
responders compared to non-responders (16.09 ± 4.21
μg/mL vs. 9.93 ± 4.56, respectively).
MMP-1 is recognized as an important mediator of
connective tissue remodeling reported to be present at
high concentrations in inflamed gingiva [37]. In the pre-
sent study, supernatant MMP levels did not demonstrate
any significant differences in response to PHT and
HPPH alone at either dose compared to untreated
macrophage cultures although we noted a trend for
higher levels of MMP-1 and MMP-3. This finding was
attributed to donor-specific variations in responses to
these agents and serve to highlight clinical observations
that approximately 50% of patients taking PHT develop
GO [1,2]. This notion is supported by the finding that
fibroblasts derived from subjects with cyclosporine-A
(CSA)-induced gingival overgrowth produce significantly
lower levels of MMP-1 than fibroblasts derived from
subjects without overgrowth [38]. In the present study,
supernatant levels of several MMPs were significantly
Figure 3 The effect of phenytoin, HPPH and LPS on levels of (A) TNF-a and (B) IL-6 in conditioned medium from macrophage
cultures. Primary human monocyte-derived macrophages (n = 6 independent cultures) were pretreated with phenytoin or HPPH (15 μg/mL
and 50 μg/mL) for 1 hour prior to challenge with 100 ng/mL A. actinomycetemcomitans LPS and the levels of TNF-a and IL-6 measured in
conditioned media after 24 hours by enzyme-linked immunosorbent assay (ELISA). TNF-a, tumor necrosis-alpha; IL, interleukin; CON, control; PHT,
phenytoin; HPPH, 5-(4-hydroxyphenyl-), 5-phenylhydantoin; LPS, lipopolysaccharide. Compared to CON, # p < 0.05, ## p < 0.01, ### p < 0.001,
compared to LPS, * p < 0.05, ** p < 0.01, *** p < 0.001. Student t-test, n = 6 independent donors.
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decreased relative to LPS-only cultures in a dose-depen-
dent manner suggesting that PHT and HPPH may miti-
gate the macrophage’s ability to degrade ECM proteins
by limiting its natural response to produce metallopro-
teinases. Such a dose response is consistent with other
studies which have demonstrated, not only a similar
effect on MMP-1 and MMP-3 at the protein and
mRNA level [39-43], but also that a threshold of serum
concentration of CSA helps to govern this mechanism
[44-49].
MMP activity is counteracted by the actions of
TIMPs. Here we report that exposure of macrophages
to LPS was associated with an increase in TIMP-1 levels
while exposure to high concentration (50 μg/mL) of
PHT and HPPH, on the other hand, significantly
reduced TIMP-1 levels. This finding is in agreement
with in-vitro and in-vivo studies which report a relative
reduction in MMP-1 and MMP-8/TIMP-1 in gingival
fibroblasts and in serum and GCF concentration in
CSA-associated gingival overgrowth subjects [50,51].
This reflects more a decrease in MMP production rather
than an increase in TIMP. In fact, this corresponds with
our findings in that supernatant levels of TIMP-1 in
samples treated with both LPS and high doses of PHT
or HPPH were not significantly different relative to
untreated controls (Fig. 2). The net effect on ECM
metabolism is based on the relative ratios of MMP and
TIMP. When MMP levels decrease and/or TIMP levels
increase, the turnover of ECM diminishes, potentially
leading to an exuberant accumulation of these proteins.
In this study, elevated levels of PHT in LPS-stimulated
macrophages were associated with decreases in both
MMP and TIMP levels. Therefore the decrease in
TIMP-1 levels was counteracted by decreases in MMP
levels. As a result, the macrophage’s synergistic relation-
ship with the fibroblast would be compromised leading
to DIGO. Indeed, monocytes (macrophage precursors)
can stimulate fibroblasts to produce MMP-1 by cell-cell
interactions while conditioned media from monocytes is
capable of inducing MMP-1 production in fibroblasts
[52]. How PHT and HPPH impact monocyte/macro-
phage-fibroblast interactions and MMP production
requires further study.
PHT is known to affect Na+ as well as Ca2+ metabo-
lism [3], (e.g., Ca2+ channels) and it is likely that this
will impact MMP/TIMP and cytokine levels [53].
Indeed, Na+ channels have been linked to activation of
macrophages and microglia [54] and accumulating evi-
dence indicates that sodium channel blockers can con-
tribute to modulation of immune functions [55]. PHT
has been reported to ameliorate the inflammatory
response associated with experimental autoimmune
encephalomyelitis in mice [54], modulate intracellular
signaling cascades to TLR ligands [56] and significantly
reduce LPS-induced phagocytosis in-vitro[53]. Here we
report a dose-dependent inhibition of macrophage func-
tion by way of suppressed supernatant levels of MMP-1,
MMP-3, MMP-9, TIMP-1 and TNF-a by PHT in
human macrophages challenged with LPS. PHT has
been reported to inhibit both activation of T-type cal-
cium channels and RANKL-induced expression of c-fos
protein in bone marrow-derived macrophages implying
that calcium signals play a role in c-fos expression [57].
PHT was also shown to inhibit NFATc1 signaling in
these cells. Further, in atrial myocytes, pharmacological
inhibition of NFAT with 11R-VIVIT almost completely
blunted the stretch-induced up-regulation of active-
MMP-2/-9 [58]. Kiode et al [57] suggested that PHT
may inhibit NFATc1 signals through suppression of c-
fos expression. Since c-fos/AP-1 regulates the expression
of numerous inflammatory cytokines and MMPs/TIMPs
via promoter AP-1 binding motif [59,60], suppression of
c-fos may provide a possible mechanism whereby
MMPs/TIMPs and possibly cytokine levels are inhibited.
In contrast to PHT we report a dose-dependent inhi-
bition of MMP-9 and TIMP-1 by HPPH in cultures
challenged with LPS. These discrepancies may be attrib-
uted to differences in the interactions of these drugs
with target molecules. Kobayashi et al [61] reported that
PHT and 5-(4-methylphenyl)-5-phenylhydantoin, which
contain a phenyl or methylphenyl group at both R2-
and R3-positions activated the ligand binding domain of
human pregane X receptor (hPXR), a member of the
nuclear receptor family of ligand-activated transcrip-
tional factors, whereas 5-(4-hydroxyphenyl)-5-phenylhy-
dantoin did not. Alternatively, it is possible that higher
concentrations of HPPH may be required to achieve
results similar to that observed with PHT as evident by
the trend for blunting of MMP-1 and MMP3 at higher
doses of HPPH (Fig. 1A, C). Nevertheless, these findings
serve to highlight the impact of PHT and HPPH, on the
macrophage’s ability to contribute to ECM turnover and
underscore the importance of Na+ and Ca2+ channels in
activated macrophages.
An interesting finding of our study was the suppres-
sion of TNF-a but not IL-6 by PHT. IL-6 enhances pro-
liferation of fibroblasts and exerts a positive effect on
collagen and glycosaminoglycan synthesis [62,63]. At
high levels, TNF-a has been reported to inhibit collagen
synthesis [64] and increase MMP synthesis in gingival
fibroblasts [65-67], which contributes to gingival break-
down. Conversely, at low levels (< 10 ng/ml) TNF-a sti-
mulates cellular proliferation, induces production of
ECM and inhibits phagocytosis of collagen by gingival
fibroblasts [68,69]. Since TNF-a enhances MMP-1 [70]
and MMP-9 [71] expression, the blunting of TNF-a
levels observed in the present study may have contribu-
ted to the decrease in supernatant levels of MMP-1 and
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MMP-9. In microglial cells, blockade of sodium chan-
nels with PHT significantly reduced LPS-induced secre-
tion of IL-1a, IL-1b, and TNF-a, but not IL-6 or IL-10
suggesting that sodium channels participate in the pro-
cess of cytokine release [53]. In agreement, we noted
specific modulation of LPS-induced TNF-a but not IL-6
in the presence of high concentrations of PHT (50 μg/
ml). Black et al [53] also demonstrated that tetrodo-
toxin, a sodium channel blocker, inhibited secretion of
IL-1a, IL-1b, and TNF-a secretion but to a lesser
degree than PHT, in spite of similar inhibitory actions
on sodium channels. This difference was likely due to
the effects on Ca2+ metabolism by PHT. It was also
interesting to note that HPPH had no effect on TNF-a
levels. As discussed above this may be due to differences
in the interactions of HPPH with target molecules or
that higher dose of HPPH is required for inhibition of
TNF-a.
In macrophages, increased TNF-a production in
response to LPS challenge is associated with a transi-
ent increase in intracellular calcium [72,73] so that
intracellular calcium may participate as a second mes-
senger in TLR4-dependent signaling [72,74]. Insight
into a possible mechanism linking intracellular calcium
and cytokine levels was recently demonstrated using
RAW macrophages [75]. Using a pharmacological
approach, Yamashiro et al [75] examined the role of
transient receptor potential vanilloin 4 (TRPV2), a cal-
cium permeable channel, in LPS-induced calcium
mobilization and induction of cytokines. They reported
that LPS-induced IL-6 production was due at least in
part by calcium mobilization solely from intracellular
sources and partly by entry of extracellular calcium
through TRPV2. Further, they reported that in addition
to calcium mobilization through the IP3-receptor,
TRPV2-mediated intracellular calcium mobilization
involved NFB-dependent TNF-a and IL-6 expression,
while extracellular calcium entry is involved in NFB-
independent IL-6 production. Collectively, these find-
ings may provide insights into how PHT and HPPH
modulate cytokine and possibly MMP/TIMP levels.
Future studies will be necessary to evaluate the impact
of these agents on intracellular and extracellular cal-
cium levels in macrophages prior to LPS challenge and
their correlation to cytokine and MMP/TIMP
production.
Conclusions
Our results demonstrate that PHT as well as its metabo-
lite, HPPH significantly blunt A. actinomycetemcomitans
LPS-induced levels of MMP-1, MMP-3, MMP-9 and
TIMP-1 in a dose-dependent manner and that a high
concentration of PHT significantly decreases TNF-a but
not IL-6 levels in the human macrophage. Given the
presence of significant numbers of macrophages in gin-
gival tissues and the correlation between the quality of
plaque control and fibrosis, our data reveals a mechan-
ism whereby both PHT and its metabolite, HPPH dysre-
gulate macrophage function. Blunting of macrophage
derived MMPs and TNF-a by these agents in response
to stimuli may permit collagen accumulation without
the counteracting production of MMPs by these cells.
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